ClinicalTrials.gg
CompletedNCT02355639Updated Feb 24, 2025

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

A Phase 1 interventional study of Clobetasol propionate 0.05 % ointment and Betamethasone dipropionate 0.064 % ointment in Skin and Connective Tissue Diseases, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to male participants aged 25 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
25 Years to 40 Years
Sex
Male
01

Study summary

The purpose of this study is to assess steroid induced skin atrophy by sonography.

02

Conditions studied

  • Skin and Connective Tissue Diseases
03

In context

Skin and Connective Tissue Diseases

20 studies on the registry are indexed under Skin and Connective Tissue Diseases; 6 are open to participants now.

This study's enrollment of 16 is below the median of 35 across 19 interventional studies indexed under Skin and Connective Tissue Diseases.

Browse Skin and Connective Tissue Diseases studies →

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers, 25 to 40 years old inclusive.
  2. Healthy skin on volar arms with a hairless area sufficient for measurements

Exclusion criteria

Exclusion Criteria:

  1. Clinical skin atrophy, telangiectasia or striae on volar arms.
  2. Presence of any skin condition or colouration that would interfere with test sites or the response or assessment.
  3. Fitzpatrick skin type IV - VI.
  4. History or current evidence of infection, eczema or other relevant skin disease.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Clobetasol propionate 0.05 % ointment

    Active drug

    Drug: Clobetasol propionate 0.05 % ointment

  • Experimental
    Betamethasone dipropionate 0.064 % ointment

    Active drug

    Drug: Betamethasone dipropionate 0.064 % ointment

  • Placebo comparator
    Petrolatum ointment

    Placebo drug

    Drug: Petrolatum ointment

06

What researchers measure

Primary outcomes

  1. Change in skin thickness from baseline to end of treatment

    Time frame: 4 weeks

Secondary outcomes

  1. Relation of clinical features (skin transparency and telangiectasia) to the steroid induced skin atrophy after end of treatment

    Time frame: 4 weeks

07

Study locations

1 site
  • Charité - Universitaetsmedizin Berlin, Department of Dermatology and Allergy
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2015
First posted
Feb 4, 2015
Start
Jan 2015
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02355639
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Feb 4, 2015
Start date
Jan 2015
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Feb 24, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clobetasol · Betamethasone dipropionate

Start the discussion